CRISPR Therapeutics AG
CRISPR Therapeutics is focused on developing gene therapies using CRISPR-Cas9 technology for the treatment of serious genetic diseases.
Price history of CRISPR Therapeutics AG
Price history of CRISPR Therapeutics AG
Performance & Momentum
Strategic Analysis
CRISPR Therapeutics AG • 2026
CRISPR Therapeutics AG is a gene therapy biotech focused on genome editing, with a highly differentiated value proposition built around CRISPR-Cas9 technology. Its positioning remains that of a high-potential R&D company, exposed to clinical and regulatory catalysts rather than to a mature industrial model.
- CRISPR-Cas9 technology at the heart of a disruptive market in genetic medicine
- Specialized positioning in severe diseases with high unmet medical need
- Ability to create value in the event of clinical success or pipeline expansion
- High dependence on clinical trial outcomes and regulatory decisions
- Still limited financial visibility, with valuation highly sensitive to execution risk
- Volatile stock market history, reflecting strong expectations followed by phases of skepticism
Momentum is constructive but remains intermediate, with a recent rebound against an underlying trend that is still uneven. The strategic view is that of a disruptive name that has become attractive again over the medium term, but which still carries a high speculative profile and requires a strong tolerance for volatility.
Similar stocks to CRISPR Therapeutics AG
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
